These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35620524)

  • 1. Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions.
    Zhang S; Li ZF; Shi HW; Zhang WJ; Sui YG; Li JJ; Dou KF; Qian J; Wu NQ
    Front Cardiovasc Med; 2022; 9():859567. PubMed ID: 35620524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.
    Mackinnon ES; Har B; Champsi S; Wani RJ; Geyer L; Shaw E; Farris MS; Anderson TJ
    Cardiol Ther; 2023 Jun; 12(2):327-338. PubMed ID: 36656500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
    Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Gao Q; Palagashvilli T; Alam S; Mues KE; Bhatt DL; Kosiborod MN;
    JAMA Cardiol; 2021 Jun; 6(9):1-9. PubMed ID: 34132735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019.
    Zheutlin AR; Derington CG; Herrick JS; Rosenson RS; Poudel B; Safford MM; Brown TM; Jackson EA; Woodward M; Reading S; Orroth K; Exter J; Virani SS; Muntner P; Bress AP
    Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008861. PubMed ID: 36252093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid management across Europe in the real-world setting: a rapid evidence review.
    Barrios V; Soronen J; Carter AM; Anastassopoulou A
    Curr Med Res Opin; 2021 Dec; 37(12):2049-2059. PubMed ID: 34517739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
    Li Z; Gao Y; Lu Q; Yin Z; Zhang S; Zhang W; Sui Y; Xu Y; Li J; Dou K; Qian J; Qiu H; Wu N
    Lipids Health Dis; 2024 May; 23(1):134. PubMed ID: 38715079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study.
    Gouni-Berthold I; Schaper F; Schatz U; Tabbert-Zitzler A; Fraass U; Sauer S; Ray KK
    Atheroscler Plus; 2022 Dec; 50():10-16. PubMed ID: 36643801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
    Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
    G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
    Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
    Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: a subanalysis of Dyslipidemia International Study II-China.
    Guo T; Chu C; Wang Y; He M; Jia H; Sun Y; Wang D; Liu Y; Huo Y; Mu J
    BMC Cardiovasc Disord; 2023 Jul; 23(1):337. PubMed ID: 37393236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
    Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
    Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study.
    Ersbøll AK; Kristensen MS; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Lytken Larsen M; Green A
    PLoS One; 2023; 18(5):e0286376. PubMed ID: 37256879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.